Table 1.
Clinical characteristics of heart failure patients.
| mRNA-Seq (n = 26) |
ncRNA-Seq (n = 42) |
ELISA (n = 36) |
|
|---|---|---|---|
| Age (years) | 53 ± 9 | 52 ± 10 | 52 ± 10 |
| Gender male (%) | 96 | 93 | 87 |
| NYHA class | III-IV | III-IV | III-IV |
| BMI (kg/m2) | 27 ± 5 | 26 ± 4 | 27 ± 6 |
| Hemoglobin (mg/dL) | 14 ± 3 | 13 ± 2 | 14 ± 2 |
| Hematocrit (%) | 40 ± 7 | 40 ± 6 | 41 ± 5 |
| Total cholesterol (mg/dL) | 155 ± 39 | 159 ± 45 | 164 ± 50 |
| Prior hypertension (%) | 25 | 31 | 21 |
| Prior smoking (%) | 71 | 71 | 75 |
| Diabetes mellitus (%) | 29 | 30 | 35 |
| LVEF (%) | 21 ± 8 | 21 ± 8 | 22 ± 9 |
| LVESD (mm) | 66 ± 12 | 61 ± 12 | 63 ± 12 |
| LVEDD (mm) | 74 ± 11 | 69 ± 12 | 71 ± 11 |
| Left ventricular mass (g) | 362 ± 142 | 316 ± 120 | 341 ± 109 |
| Left ventricle mass index (g/m2) | 194 ± 76 | 166 ± 60 | 180 ± 65 |
| Duration of disease (months) # | 59 ± 56 | 44 ± 38 | 57 ± 52 |
NYHA, New York Heart Association; BMI, body mass index; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVEDD, left ventricular end-diastolic diameter. # Duration of disease from diagnosis of heart failure until heart transplant.